GlassScriptPhysician profile
Dana K Delaski
NPI 1467753772
$158,130.81
in general payments reported to CMS, 2019-2025
73 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39K · 2022: $53K · 2023: $40K · 2024: $13K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Travel and Lodging: $17K · Food and Beverage: $10K · Consulting Fee: $1,808 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,280.00 |
| Travel and Lodging | $17,209.49 |
| Food and Beverage | $10,215.33 |
| Consulting Fee | $1,807.50 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $144,456.29 | 2021-2025 | Jakafi, Monjuvi, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,862.27 | 2021-2025 | Iclusig, Alunbrig, Fruzaqla |
| Vertex Pharmaceuticals Incorporated | $931.76 | 2022 | |
| Celgene Corporation | $766.26 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $560.02 | 2021-2025 | |
| Genzyme Corporation | $549.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $528.84 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Beigene USA, INC. | $474.75 | 2021-2024 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $458.11 | 2021-2025 | Ultomiris |
| Janssen Biotech, INC. | $427.46 | 2021-2025 | Tecvayli, Darzalex, Rybrevant |
| Genentech USA, INC. | $387.74 | 2021-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $373.51 | 2021-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $352.62 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $326.91 | 2021-2025 | |
| Pharmacosmos Therapeutics INC. | $297.56 | 2021-2024 | Monoferric, Cosela |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $291.86 | 2021-2025 | Rezlidhia, Gavreto, Tavalisse |
| Astellas Pharma US INC | $285.71 | 2021-2025 | Cresemba, Vyloy, Xospata |
| Pfizer INC. | $264.52 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $230.69 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $230.00 | 2024-2025 | Talvey |
| Kite Pharma, INC. | $229.10 | 2022-2023 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $227.21 | 2021-2023 | Imbruvica, Epkinly |
| Amgen INC. | $208.30 | 2021-2022 | |
| Blueprint Medicines Corporation | $204.16 | 2021-2025 | Ayvakit |
| Glaxosmithkline, LLC. | $180.51 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Emmaus Medical, INC. | $177.22 | 2021-2024 | Endari |
| Karyopharm Therapeutics INC. | $166.00 | 2021-2025 | Xpovio |
| Sanofi-Aventis U.S. LLC | $161.09 | 2021-2025 | |
| Seagen INC. | $155.43 | 2021-2023 | Adcetris |
| Daiichi Sankyo INC. | $149.15 | 2021-2025 | Vanflyta, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $146.87 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $132.09 | 2023-2025 | Clonoseq |
| Alnylam Pharmaceuticals INC. | $127.92 | 2022-2025 | Givlaari |
| Puma Biotechnology, INC. | $116.44 | 2021-2024 | |
| Immunocore Limited | $107.90 | 2023-2025 | Kimmtrak |
| Stemline Therapeutics INC. | $104.03 | 2024-2025 | Orserdu |
| Pharmaessentia USA Corporation | $103.73 | 2024-2025 | Besremi |
| Taiho Oncology, INC. | $96.29 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $95.88 | 2022-2025 | Lynozyfic, Libtayo |
| Emd Serono, INC. | $93.08 | 2021-2024 | Bavencio |
| Sobi, INC | $89.91 | 2024-2025 | |
| Morphosys, US INC. | $63.57 | 2021-2023 | Monjuvi |
| Genentech, INC. | $62.28 | 2021 | |
| Servier Pharmaceuticals LLC | $57.46 | 2021-2025 | |
| Adc Therapeutics America, INC. | $57.01 | 2024-2025 | |
| Beone Medicines USA, INC. | $52.57 | 2025 | Brukinsa, Tevimbra |
| Legend Biotech USA INC. | $48.28 | 2024-2025 | Carvykti |
| Novo Nordisk INC | $45.70 | 2025 | |
| Jazz Pharmaceuticals INC. | $44.03 | 2024-2025 | |
| Acceleron Pharma, INC. | $41.27 | 2021 | |
| Sanofi US Services INC. | $40.23 | 2025 | |
| Aveo Pharmaceuticals, INC. | $39.44 | 2024-2025 | |
| Myovant Sciences INC. | $36.99 | 2021 | |
| Array Biopharma INC | $32.02 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Bard Peripheral Vascular, INC. | $31.37 | 2022-2024 | Trek |
| Eisai INC. | $30.53 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.79 | 2024-2025 | Gilotrif |
| Gilead Sciences, INC. | $28.32 | 2025 | Trodelvy |
| Geron Corporation | $24.59 | 2025 | Rytelo |
| Genmab U.S., INC. | $22.23 | 2023 | Tivdak |
| G1 Therapeutics, INC. | $21.27 | 2023 | Cosela |
| Recordati_rare_diseases_inc. | $20.53 | 2024 | Sylvant |
| Acrotech Biopharma INC. | $18.22 | 2021 | |
| Epizyme, INC. | $18.01 | 2021 | |
| Agios Pharmaceuticals, INC. | $17.87 | 2025 | Pyrukynd |
| Dova Pharmaceuticals | $17.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.80 | 2021 | |
| Lilly USA, LLC | $16.61 | 2023 | Jaypirca, Verzenio |
| Springworks Therapeutics, INC. | $14.63 | 2025 | Gomekli |
| Tolmar, INC. | $14.02 | 2023 | |
| Caris Mpi, INC. | $13.72 | 2025 | Mi Cancer Seek |
| Kyowa Kirin, INC. | $12.91 | 2021 | |
| Secura Bio, INC. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Delaski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.